203 related articles for article (PubMed ID: 34428596)
1. Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China.
Kang Y; Zhou Q; Cui J
J Glob Antimicrob Resist; 2021 Dec; 27():67-71. PubMed ID: 34428596
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
[No Abstract] [Full Text] [Related]
3. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
5. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
[TBL] [Abstract][Full Text] [Related]
6. In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.
Shen S; Tang C; Yang W; Ding L; Han R; Shi Q; Guo Y; Yin D; Hu F
Emerg Microbes Infect; 2024 Dec; 13(1):2356146. PubMed ID: 38743401
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms Driving the
Li X; Ke H; Wu W; Tu Y; Zhou H; Yu Y
mSphere; 2021 Dec; 6(6):e0085921. PubMed ID: 34935448
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
Bianco G; Boattini M; Comini S; Iannaccone M; Bondi A; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):63-70. PubMed ID: 34462816
[TBL] [Abstract][Full Text] [Related]
9. In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.
Guzmán-Puche J; Pérez-Nadales E; Pérez-Vázquez M; Causse M; Gracia-Ahufinger I; Mendez-Natera A; Allalou-Ruiz Y; Elías C; Oteo-Iglesias J; Torre-Cisneros J; Martínez-Martínez L
Int J Antimicrob Agents; 2022 Feb; 59(2):106524. PubMed ID: 35038557
[TBL] [Abstract][Full Text] [Related]
10. Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series.
van Asten SAV; Boattini M; Kraakman MEM; Bianco G; Iannaccone M; Costa C; Cavallo R; Bernards AT
J Infect Chemother; 2021 May; 27(5):778-780. PubMed ID: 33558042
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Ceftazidime-Avibactam in Two Patients With KPC-Producing Klebsiella pneumoniae Bacteremia and Renal Impairment.
Veillette JJ; Truong J; Forland SC
Pharmacotherapy; 2016 Nov; 36(11):e172-e177. PubMed ID: 27716983
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
[TBL] [Abstract][Full Text] [Related]
13. Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant
Wu Y; Yang X; Liu C; Zhang Y; Cheung YC; Wai Chi Chan E; Chen S; Zhang R
Microbiol Spectr; 2022 Apr; 10(2):e0265521. PubMed ID: 35416703
[TBL] [Abstract][Full Text] [Related]
14. KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae.
Findlay J; Poirel L; Juhas M; Nordmann P
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0089021. PubMed ID: 34228551
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment.
Wang F; Zhou Q; Yang X; Bai Y; Cui J
PLoS One; 2021; 16(10):e0258426. PubMed ID: 34648556
[TBL] [Abstract][Full Text] [Related]
16. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
[TBL] [Abstract][Full Text] [Related]
17. Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient.
Gaibani P; Gatti M; Rinaldi M; Crovara Pesce C; Lazzarotto T; Giannella M; Lombardo D; Amadesi S; Viale P; Pea F; Ambretti S
Int J Infect Dis; 2021 Dec; 113():213-217. PubMed ID: 34656787
[TBL] [Abstract][Full Text] [Related]
18. Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model.
Barber KE; Pogue JM; Warnock HD; Bonomo RA; Kaye KS
J Antimicrob Chemother; 2018 Sep; 73(9):2405-2410. PubMed ID: 29939267
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Ceftazidime/Avibactam Administration in
Dai Y; Chang W; Zhou X; Yu W; Huang C; Chen Y; Ma X; Lu H; Ji R; Ying C; Wang P; Liu Z; Yuan Q; Xiao Y
Drug Des Devel Ther; 2021; 15():2899-2905. PubMed ID: 34262257
[TBL] [Abstract][Full Text] [Related]
20. Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant
Oliva A; Campogiani L; Savelloni G; Vitale P; Lodi A; Sacco F; Imeneo A; Volpicelli L; Polani R; Raponi G; Sarmati L; Venditti M
Open Forum Infect Dis; 2023 Jul; 10(7):ofad327. PubMed ID: 37476077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]